Eli Lilly and Co
2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit
The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating their obesity with GLP-1 drugs. Early on, there were manufacturing bottlenecks that resulted in short supplies of Novo Nordisk ‘s Wegovy and Eli Lilly ‘s Zepbound. There were insurance coverage issues for these pricey treatments, […]
Read More
Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market
Still life of the big three injectable prescription weight loss medicines. Ozempic, Victoza and Wegovy. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Ucg | Universal Images Group | Getty Images Novo Nordisk’s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker […]
Read More
Novo Nordisk’s ‘long game’ on weight loss drugs sparks hope in science, but the Street is impatient
Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup […]
Read More
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]
Read More
Novo Nordisk’s new obesity pill, Alphabet’s data center deal, the end of EV euphoria and more in Morning Squawk
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Here are five key things investors need to know to start the trading […]
Read More
Shares in Wegovy-maker Novo Nordisk pop 6% after GLP-1 pill approval
Shares in Novo Nordisk surged 6% Monday, after the Wegovy maker secured approval of its GLP-1 pill — a world first. The U.S. Food and Drug Administration’s approval of Novo Nordisk’s GLP-1 pill gives the Danish pharmaceutical giant a head start over U.S. rival Eli Lilly. The pill’s starting dose of 1.5 milligrams will be […]
Read More
Stock futures are little changed after S&P 500 notches three-day win streak: Live updates
Traders work on the floor of the New York Stock Exchange (NYSE) in New York, US, on Monday, Dec. 22, 2025. Michael Nagle | Bloomberg | Getty Images Stock futures traded near the flatline Monday night after a strong start to a shortened trading week. Futures tied to the Dow Jones Industrial Average lost 5 […]
Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]
Read More
These are the world’s most important stocks heading into 2026, according to Bank of America
The most important companies in the global stock market come down to just 20 names — and they can wield significant influence over investors’ portfolios going into the new year, a Bank of America analysis found. Most of the S & P 500’s 16% run this year can be attributed to a select few Big […]
Read More
Nine of the largest pharma companies ink deals with Trump to lower drug prices
President Donald Trump signs an executive order aimed at reducing the cost of prescription drugs and pharmaceuticals by 30% to 80% during an event in the Roosevelt Room of the White House on May 12, 2025, in Washington, DC. Andrew Harnik | Getty Images Several of the largest U.S. and European-based drugmakers inked deals with […]
Read More